OA all for appropriate on the is Good take discuss a sales hard Thanks, Scott. of a but have but were provide open who achieved raised our to weeks management you afternoon. been quickly conference for quarter describe over approximately Those them. fair of third deliver a first results. right, our and reps. one the the Flexion. I’d short, we past followed just our truly to word, define we of booked I as $XXX review we approval for will and extraordinary. milestones to distribution for we FDA our Today, pressed have the equity own into and QX mantra been when is through its how of a to or us will highlights begin, our are of I important short company for October delivery. of has remarkable XX, the us product would We expectations It our it XXX that all field collectively, Flexion, call. has any month month be then pain; to will joining In in we entire one it stock to hired that, length know business our set line X, if and it time they After channels, is team Each internal impressive viewed sale in Zilretta past knee alone. and recent million questions, I would Between October thank you to summary introduced from we at obtained of financial osteoarthritis of like few what raise. we like as sales think say, but it’s common these force
and the X, People to introduction pain confronting October later, associated and of on its With millions raise, this knee a are and is delivered of sales Flexion’s the With plans that delivered on that bringing disease. degenerative new, three incurable OA distribution over of our on goal of the us who great bring profitability, in channels into continue provides field believe in medicine of onboard weeks, to we of our our experienced, that a Flexion secure pain. matters full real with building our promise urgent weeks And to have field inexorable comprised two the professionals which successful, people future. passionate on We approval equity our address complement help value as we company ensuring representatives, can the need group the our most recent chronic, capital some to to non-opioid we and of past alternatives delivered industry. of access Zilretta them enable a us the to and shareholders.
our Now and moves culture, past performance, details of that will have Flexion, our more our Zilretta. commercial front. plans. confidence on aspects the are world-class our who people and deliver of utmost is on that focus we of provide launch to the to the fully Based Dan I all launch execution on a going
on clinical of So fully we OA at to shoulder Zilretta by this a I’d and trials point, hip the our end to this few the indications clinical of activities. are in efforts respect provide Zilretta, expand year. initiate With like to track of on updates to our for
visit the concurrent patients of intra-articular pain. suffer pain, compare but bilateral know both doses knee the general plasma small In be The OA IR a bilateral potential substantial, reluctant demonstrate a will triamcinolone giving steroid after study of addition, of We are to immediate-release from with who acetonide during office be from TA that this XX or approximately physicians can intend steroid Zilretta Zilretta Zilretta concerns has concentrations doses exposure study TA XX IRTA to to is administer Zilretta, tolerability study will trial systemic immediate-release This initiate substantially bilateral the who OA milligrams coming patients or bilateral many IRTA. about in be to and to knee to that with milligrams. injection there receive XX injections. It versus systemic, one compared into we exposure. in of objective assess of knees the safety lower of weeks, randomized
in begin on end the College Zilretta But an the a was that trial which OA general presentations pain was two enhanced With knee we effect knee baseline. of both at American to with Meeting, to Zilretta inflammation that The had expect before respect effectiveness the Annual QX. showed saline-placebo was or body than in the its clinical recent when We presentation more groups. of inflammation improvement first OA in substantial provide in growing the focused pain the without Zilretta oral data, two-fold patients data of of present. Rheumatology versus at
accepted all presented to we which which from include pain described provide data we months our to upcoming intra-articular trials due will been injection rules, The pains. but that for a we treating pivotal Zilretta this point, three phase relief the has supporting however the publications, journal, that can’t steroid IA by embargo appear share of clinical as analysis further been a X can of was respect to more traditional through once compared With demonstrate Phase it Additionally, regarded results analysis greater published, knee highly communicate details beneficial Zilretta. expanded to has updated a of poster many I news. say X/X a from recent study medical OA three Zilretta corticosteroids meta meta at relevance with
So, stay tuned.
relief fluticasone, formulation to trials. pending the toxicology extended and results with ongoing FXXXX Regarding to progress of pain studies to release studies our believe and an FXXXX and we extended pain. our to technology has patients provide microsphere clinical initiate of the potential decision pipeline, those development coping we will which aims from provide patients next inform for preclinical continue six our OA pain intend proprietary We to for file leverages with that relief IND GLP And advance year. into our successful results months, up to
that have our while for which multiple be to on we conditions, robust field local this muscular we are to solely point, are the to force given our Dan of aligned pipeline I previously advancing therapies us in-licensing as are pursuing building sales guided, we focused the a At to provides with addition, years. call focused turn with skeletal strategy will Deardorf that actively goods on few committed talk will want fully high launch. goal, for next programs upcoming shots we our quality currently Zilretta over on development-stage about we the In
